ELF2: A Drug Target / Disease Biomarker (G1998)
ELF2: A Drug Target / Disease Biomarker
ELF2, also known as EXT2, is a gene that encodes for a protein known as EXT2, which is a key regulator of the angiogenesis process in the body. Angiogenesis is the process by which new blood vessels are formed, and this process is critical for the development and maintenance of tissues throughout the body.
The discovery of ELF2 as a potential drug target or biomarker has significant implications for the treatment of various diseases, including cancer, cardiovascular disease, and neurological disorders.
ELF2 and EXT2
The EXT2 gene encodes for the EXT2 protein, which is a 26-kDa transmembrane protein that plays a critical role in regulating angiogenesis. The EXT2 protein is composed of four transmembrane domains, including an N-terminal domain that contains a nucleotide-binding oligomerization domain (NBO), a protein-coding domain, and a C-terminal domain that contains a leucine-rich repeat (LRR) domain and acaline-rich repeat (AR).
The NBO domain of EXT2 is a key regulator of the Angiogenesis Regulatory Protein (ANGPP) signaling pathway. This pathway is critical for the regulation of angiogenesis by promoting the formation of blood vessels and the growth of new capillaries. The NBO domain of EXT2 is responsible for the formation of a protein-protein interaction network that regulates the activity of the ANGPP signaling pathway.
ELF2 and cancer
ELF2 has been shown to be highly expressed in various types of cancer, including breast cancer, lung cancer, and colon cancer. In addition, studies have shown that high levels of ELF2 are associated with poor prognosis in cancer patients.
One potential mechanism by which ELF2 contributes to cancer development is by promoting the angiogenesis that occurs during the early stages of cancer development. By promoting the formation of new blood vessels, ELF2 may be contributing to the development of new tumors that are characterized by the formation of new blood vessels.
ELF2 and cardiovascular disease
ELF2 has also been shown to be expressed in the hearts and blood vessels, and studies have suggested that it may play a role in the development and progression of cardiovascular disease.
One potential mechanism by which ELF2 contributes to cardiovascular disease is by contributing to the development of atherosclerosis, a condition in which plaque builds up in the arteries and can cause heart attacks and other cardiovascular events. Studies have shown that ELF2 is involved in the regulation of the production of plaque in the arteries, and that high levels of ELF2 are associated with an increased risk of cardiovascular disease.
ELF2 and neurological disorders
ELF2 has also been shown to be involved in the development and progression of neurological disorders, including Alzheimer's disease and Parkinson's disease.
One potential mechanism by which ELF2 contributes to neurological disorders is by contributing to the development of neurodegeneration that occurs in these conditions. Studies have shown that ELF2 is involved in the regulation of the production of neurodegenerate protein, and that high levels of ELF2 are associated with an increased risk of developing neurodegenerative disorders.
Drug targeting and biomarker potential
The discovery of ELF2 as a potential drug target or biomarker has significant implications for the treatment of various diseases.
Targeting ELF2
One potential approach to targeting ELF2 is to use small molecules or antibodies that can inhibit the activity of the NBO domain of EXT2. This would reduce the formation of the protein-protein interaction network that regulates the ANGPP signaling pathway and potentially reduce the number of new blood vessels that form during angiogenesis.
Another potential approach to
Protein Name: E74 Like ETS Transcription Factor 2
Functions: Isoform 1 transcriptionally activates the LYN and BLK promoters and acts synergistically with RUNX1 to transactivate the BLK promoter
The "ELF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELF2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor
